LONDON – Oxford Biodynamics plc claims its epigenetic biomarker technology has cracked the problem of singling out the half of newly diagnosed rheumatoid arthritis (RA) patients who will not respond to methotrexate, potentially ending one of the major challenges in managing the disease and opening the way for patient stratification in clinical trials.